French pharma company to relocate production to Turkey

Yeni Şafak /AA - French pharmaceutical company Servier has announced plans to move some of its production Turkey from its plants in Ireland and France. The company plans to produce 21 million packages in Turkey over the next 18 months through local drug manufacturers Abdi İbrahim and İlko İlaç.

Speaking at a press event announcing the deal, Philippe Mea, General Manager of Servier Turkey, said the company would raise production capacity in Turkey to 32 million packages by 2018. “This figure may go up when exports to neighbours are considered,” he noted.

“97 percent of Servier medicines sold in Turkey will be produced locally in the coming 18 months,” Mea said, adding that Servier had been active in Turkey for the last 38 years and producing 6 million packages in the country annually in cooperation with Abdi İbrahim.

“We place great emphasis on Turkey’s economic power as well as its growing pharmaceutical market. Servier considers Turkey a motherland,” Mea said, adding that the local production would help Turkey to reach its 2023 goals, the Republic’s centennial.

Among these goals is to become one of the top-10 economies of the world, reach an exports total of USD 500 billion and increase R&D expenditures to 3% of GDP.

Turkey; pharmaceuticals; turkey pharma market; servier turkey; turkey pharma production